@article{e535863bee234f2d804ac2d337b4f3f3,
title = "Phase I/II study of AT-101 in combination with topotecan in patients with relapsed or refractory small cell lung cancer after prior platinum containing first line chemotherapy",
author = "Heist, \{R. S.\} and Molina, \{J. R.\} and Urba, \{W. J.\} and Mirshahidi, \{Hamid R.\} and S. Grunberg and J. Maleski and V. Brainerd and L. Leopold and Lynch, \{T. J.\}",
note = "Background: Antiapoptotic members of the Bcl-2 protein family are expressed in the tumor tissue of the majority of patients (pts) with small cell lung cancer (SCLC) and are associated with chemo-resistance. AT-101, an oral, pan Bcl-2 family protein inhibitor has demonstrated activity in SCLC models, including those that express Mcl-1 and are resistant to other Bcl-2 inhibitors.",
year = "2008",
month = may,
day = "20",
doi = "10.1200/jco.2008.26.15\_suppl.19004",
language = "American English",
volume = "26",
pages = "19004--19004",
journal = "Journal of Clinical Oncology",
number = "15\_suppl",
}